EUS Guided HVA and PVA for Circulating Tumor DNA in Patients

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 1, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new way to look for cancer-related DNA in the blood of patients with certain gastrointestinal cancers, specifically stage II-IV distal gastric cancer, pancreatic cancer, or colorectal cancer. Researchers will use a procedure called endoscopic ultrasound (EUS) to carefully collect blood samples from the liver and portal vein to see how much of this tumor DNA, known as circulating tumor DNA (ctDNA), is present. The goal is to learn if measuring ctDNA can help doctors better stage the cancer before surgery, check how well treatment is working, and monitor for any signs of cancer returning after treatment.

To be eligible for this trial, participants must be at least 18 years old and newly diagnosed with one of the targeted cancers. They should be planning to undergo treatments like surgery, chemotherapy, or radiation. However, those with certain conditions, like other active cancers or severe blood clotting issues, may not qualify. Participants can expect to undergo a safe procedure to collect blood samples, and the study aims to provide valuable information that could improve cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Age \>= 18 years old
• • 2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
• 3. Undergoing treatment with either:
• • 1. Surgery
• • 2. Neoadjuvant chemotherapy
• • 3. Neoadjuvant chemoirradiation
• • 4. Palliative chemotherapy/ immunotherapy
• Exclusion criteria:
• • <!-- -->
• • 1. Synchronous cancer of other sites
• • 2. Cardia, high lesser curve tumors, oesophagogastric junction tumors
• • 3. Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
• • 4. Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
• • 5. Patients unwilling to undergo follow-up assessments
• • 6. Patients with liver cirrhosis, portal hypertension and/ or gastric varices
• • 7. Patient refusal to participate
• • -